CNS Drug Discoveries: Schizophrenia Chapter

Table of Contents

SCHIZOPHRENIA

• EXECUTIVE SUMMARY
• THE FACTS
  • What is schizophrenia and why are we interested in it?
    • Symptoms associated with schizophrenia
    • Schematic depicting mood swings in bipolar disorder
• PATIENT STATISTICS
  • Incidence, diagnosis rates and treatment; now and in the future
• PATIENT MODEL
  • Summary of patient population forecasts 2005A-2012E
• DRUG GROWTH DRIVERS
• DRUG GROWTH RISKS/DAMPENERS

GLOBAL SCHIZOPHRENIA MARKET

• Global CNS Market (US$68.7 billion)
• GLOBAL SALES SPLIT
  • Global sales split (2005A)
  • Prescription usage split (2005A)
  • The major players
    • Market share of antipsychotic players by sales (Dec 2005A)
    • Market share of antipsychotic players by sales (Dec 2006E)
  • Players and Products in 2005 & 2006
  • Players and Products in 2012
    • Market share of antipsychotic players by sales (Dec 2012E)
• CURRENT TREATMENTS
  • Leading Brands
    • Comparison of leading antipsychotic drugs
  • Current Products Patent Exposure
    • Patent Exposure of Leading Antipsychotic Brands
• ANALYSIS OF LEADING BRANDS
  • Atypical antipsychotics
  • Other Agents
• ATYPICAL ANTIPSYCHOTICS
  • Abilify (Bristol-Myers Squibb/Otsuka)
  • Geodon/Zeldox (Pfizer)
  • Risperdal (Johnson & Johnson)
  • Seroquel (AstraZeneca)
  • Zyprexa (Eli Lilly)
• Other atypical antipsychotics:
  • Serdolect (Lundbeck)
  • Lullan
  • Clozaril/Leponex (Novartis)
  • Solian (sanofi-aventis)
• GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2005 - 2012
  • Sales Forecasts of Current Leading Antipsychotics
  • Model assumptions
• NEW DRUGS IN R&D
  • Drugs in Development to Treat Schizophrenia and Bipolar Disorder
• ANALYSIS OF PHASE III DRUGS
  • Drugs in Phase III Development to Treat Schizophrenia and Bipolar Disorder
  • D/5-HT receptor antagonists
• D/5-HT receptor antagonists
  • Asenapine (Pfizer/Organon)
  • Bifeprunox (Wyeth/Solvay/Lundbeck)
  • Blonanserin (Dainippon Sumitomo)
    • Clinical Efficacy of Blonanserin
  • Iloperidone (Vanda Pharmaceutical)
    • Safety Profile of Iloperidone vs. Approved Antipsychotics
  • Paliperidone (Johnson & Johnson)
• GLOBAL SALES FORECASTS OF PHASE III SCHIZOPHRENIA DRUGS 2006 - 2012
  • Sales Forecasts of Phase III Developmental Antipsychotic Drugs
  • Model assumptions
• ANALYSIS OF PHASE II DRUGS
  • New Drugs in Early Clinical Development to Treat Schizophrenia/Bipolar Disorder
  • Lurasidone (Dainippon Sumitomo/Merck & Co.)
  • Ocaperidone (Neuro3d)
  • SGS518 (Eli Lilly/Saegis Pharmaceuticals)
  • Talnetant (GlaxoSmithKline)
    • Talnetant Efficacy and Safety Profile
    • Talnetant Cognitive Effects
  • ABT-089 (Abbott)
  • ORG 24448 (Akzo Nobel/Cortex Pharmaceuticals)
  • Vabicaserin (Wyeth)
• GLOBAL SALES FORECASTS OF PHASE II ANTIPSYCHOTIC DRUGS 2005-2012
  • Sales Forecasts of Phase II Developmental Antipsychotic Drugs
  • Model assumptions
• COMPETITOR RATIO ANALYSIS
  • CR Analysis of Antipsychotic Agents Approved by 2012 - Based on Drug Class
• COMPETITOR RATIO ANALYSIS - COMPANIES
  • CR Analysis of Antipsychotics Approved by 2012 - Based on Company
  • WINNERS & LOSERS
    • Summary of Key Companies and Drugs in the Antipsychotic Market by 2012
  • Winners
  • Losers
• DISCONTINUATION OF DRUGS
  • Antipsychotic Drugs Discontinued from Clinical Development
• SCHIZOPHRENIA APPENDIX 1
  • Assessment of antipsychotic efficacy in schizophrenia
  • Assessment of antipsychotic efficacy in bipolar disorder
• SCHIZOPHRENIA APPENDIX 2
  • Phase transition probability
    • Probability of launch
• SCHIZOPHRENIA APPENDIX 3
  • Patient Model
    • Summary of US Schizophrenia Patient Population Forecasts
    • Summary of European (Top 5) Schizophrenia Patient Population Forecasts
    • Summary of Japanese Schizophrenia Patient Population Forecasts
• SCHIZOPHRENIA APPENDIX 4
  • Global Antipsychotic Drug Sales 2005A-2012E
• SCHIZOPHRENIA APPENDIX 5
  • Competitor Ratio Analysis Criteria
    • Key Antipsychotic Drugs on the Market by 2012
• SCHIZOPHRENIA GLOSSARY
• SCHIZOPHRENIA REFERENCES
• ACRONYMS